[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"benign-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:benign-neoplasm":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100495050","phase-4-fluid-challenge-and-plasma-volume-during-surgery-100495050",false,"NCT05726136","Fluid Challenge and Plasma Volume, During Surgery","Comparison of Albumin and Ringer's Solution for Optimization of the Plasma Volume and Hemodynamics During Laparoscopic Surgery.","FC-VE","Inclusion Criteria:\n\n* Written consent to participate in the study\n* For women: relevant contraceptive, menopausal or a negative pregnancy test.\n* ASA category I to III\n* Laparoscopic abdominal surgery, with a duration of at least 90 minutes.\n* 18 to 85 years\n\nExclusion Criteria:\n\n* Patients with known cardiac failure\n* \\\u003C18 or \\>85 years\n* known allergy to albumin\n* extracellular hyperhydration or hypervolemia\n* kidney failure\n* pregnancy or planned pregnancy","ALL","18 Years","85 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","A short bolus infusion of fluid, called \"fluid challenge\" is commonly recommended for fluid treatment during longer surgery. However a prolonged increase of the blood volume is a prerequisite to recommend the technique. The purpose with the study is to examine the plasma expanding effect of three different fluid challenge strategies (acetated Ringers 4 ml\u002Fkg body weight, albumin 5% 4 ml\u002Fkg body weight or albumin 20% 1 ml\u002Fkg body weight), using hemoglobin as a dilution indicator.",[28,29,30,31,32],"Colorectal Cancer","Urologic Cancer","Gynecologic Cancer","Colorectal Disorders","Benign Neoplasm",[34],"laparoscopic surgery, fluid therapy, plasma volume","RECRUITING","2026-04-24",{"date":38,"type":39},"2026-04-30","ACTUAL",{"date":41,"type":39},"2023-10-23",{"date":43,"type":22},"2026-10-31",{"name":45,"class":46},"Joachim Zdolsek","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":47},"100420238","phase-2-intraoperative-tumor-margin-identification-with-icg-dye-imaging-100420238","NCT04752137","Intraoperative Tumor Margin Identification With ICG Dye Imaging","Evaluation of Intraoperative Tumor Margin Identification With Fluorescent Dye Imaging","Inclusion Criteria:\n\n* All patients 18 years of age or older who present to Massachusetts General Hospital Department of Orthopaedic Surgery with a benign or malignant bone or soft tissue mass that is consented for surgery during the study period.\n\nExclusion Criteria:\n\n* Pregnant or nursing patients\n* Patients with previously known anaphylaxis to IV contrast or iodine (other allergies may be considered on a case-by-case basis)\n* Patients in renal failure who are not cleared for ICG administration by their primary physician or oncologist",{"count":56,"type":22},100,[58],"PHASE2","In this research study we want to learn more about the use of indocyanine green (ICG) during bone or soft tissue mass resections. Indocyanine green (ICG) is a type of dye that is used in medical diagnostics. We want to determine if ICG-guided tumor resection is more effective in obtaining negative margins. Lastly, we want to assess traditional oncologic outcomes of local recurrence, time to metastatic disease, and overall and disease specific survival.",[32,61],"Malignant Neoplasm","2026-04-21",{"date":36,"type":39},{"date":65,"type":39},"2022-05-25",{"date":67,"type":22},"2030-04-01",{"name":69,"class":46},"Massachusetts General Hospital",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":77,"enrollmentInfo":4,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":87,"locationsCount":47},"100333818","bone-marrow-transplantation-using-cd34-selected-stem-cells-from-related-or-unrelated-donors-in-treating-participants-with-cancer-or-other-disorders-100333818","NCT03626285","Bone Marrow Transplantation Using CD34-Selected Stem Cells From Related or Unrelated Donors in Treating Participants With Cancer or Other Disorders","Institutional Protocol of Bone Marrow Transplantation Using CD34-Selected Peripheral Blood Stem Cells From Related Haploidentical or Unrelated Donors for Treatment of Malignant and Nonmalignant Disorders","Inclusion Criteria:\n\n* Patients with malignant or nonmalignant diseases that can benefit from alternative stem cell transplantation according to institutional standard practice guidelines\n* Patients lacking a healthy human leukocyte antigen (HLA)-identical related donor and having one of the following alternative donor sources:\n\n  * HLA-haploidentical related (HLA antigen genotypic match \\>= 4\u002F8 and \\\u003C= 7\u002F8) or\n  * Unrelated donor that is HLA matched at \\>= 7\u002F8 HLA antigen loci\n* The selected donor must also be:\n\n  * Able to receive granulocyte colony-stimulating factor (G-CSF, filgrastim) and undergo apheresis either through placement of peripheral or temporary central venous catheter, based on institutional guidelines for peripheral blood stem cell collection\n  * Meet all institutional standard criteria for clearance for peripheral stem cell collection\n* Recipients must meet institutional treatment standards based on pre-transplant evaluations including:\n\n  * Adequate major organ functions\n  * Free of major systemic infections\n  * Not pregnant, if female of childbearing age (post-pubertal)\n* Recipient (if \\>= 18 years) or their parent\u002Flegal guardian (if \\\u003C 18 years) must be able to sign the informed consent form for the treatment plan; assent will be obtained from recipients 7-17 years of age, in accordance to our institutional guidelines\n\nExclusion Criteria:\n\n* Patients not meeting clearance criteria for bone marrow transplantation (BMT) based on standard institutional guidelines\n* Presence of anti-HLA antibodies against donor antigens in a recipient or anti-HLA antibodies against recipient antigens in a donor\n* Known allergy to murine (mouse) protein or iron-dextran","70 Years","EXPANDED_ACCESS","This expanded access protocol studies bone marrow transplantation using CD34-selected stem cells from related or unrelated donors in treating participants with cancer or other disorders. Stem cells collected from the donor will be processed using a new device called CliniMACS CD34 Reagent System which marks the blood cells collected from the donor with a special protein called \"antibody\" that tags only the donor stem cells, sorting out other cells of the blood and immune system. This is done to remove, at least partially, some of the T cells. T cells are the cells in the blood that work as scavengers of the immune system deciding what belongs and what does not. These cells can sometimes cause rejection of the donor graft or a condition called graft-versus host disease (GVHD), where the donor cells can attack the body of the recipient. A bone marrow transplantation using CD34-selected stem cells may reduce the risk of these unwanted side effects of transplant as much as possible.",[32,81,82,61],"Bone Marrow Transplantation Recipient","Hematopoietic Cell Transplantation Recipient","AVAILABLE","2025-12-29",{"date":86,"type":39},"2026-01-02",{"name":88,"class":46},"OHSU Knight Cancer Institute"]